Incannex Healthcare Inc ARS, filed Oct 28, 2026

Incannex Healthcare Inc. (IXHL)

Incannex Healthcare Inc. reports that its IHL-42X Phase 2 safety and efficacy study comparing 9 doses commenced July 2026; its Phase 2/3 and bioavailability studies are completed. AI summary